Subtype
Lung Neuroendocrine Neoplasm
CI-CAN-00001096Explore in graph →
Non-malignant399 active trials6 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001096Explore in graph →
Clinical trials
1,149 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06332950 | Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy | not yet recruiting | Phase 1 / Phase 2 | 80 | Baohui HanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06306560 | A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. | not yet recruiting | Phase 2 | 40 | Harbin Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT06236997 | Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | not yet recruiting | Phase 2 | 48 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05703997 | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction(FASTIMMUNE) | not yet recruiting | Phase 2 | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT05484583 | Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases | not yet recruiting | Phase 2 | 58 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Aug 5, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Mar 27, 2024source: clinicaltrials